These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 23799855

  • 1. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
    Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J, TUGAMO GROUP.
    Br J Cancer; 2013 Jul 09; 109(1):121-30. PubMed ID: 23799855
    [Abstract] [Full Text] [Related]

  • 2. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
    de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J.
    Br J Cancer; 2013 Jun 25; 108(12):2565-72. PubMed ID: 23722472
    [Abstract] [Full Text] [Related]

  • 3. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE.
    J Thorac Oncol; 2008 Mar 25; 3(3):228-36. PubMed ID: 18317064
    [Abstract] [Full Text] [Related]

  • 4. Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.
    Rief H, Omlor G, Akbar M, Bruckner T, Rieken S, Förster R, Schlampp I, Welzel T, Bostel T, Roth HJ, Debus J.
    BMC Cancer; 2016 Mar 17; 16():231. PubMed ID: 26983672
    [Abstract] [Full Text] [Related]

  • 5. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B.
    Ann Oncol; 2007 Jul 17; 18(7):1165-71. PubMed ID: 17442659
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
    Hu XY, Zou QF, Jin C, Li WD, Chen WS, Ma L.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun 17; 30(6):1343-6. PubMed ID: 20584674
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
    Søe K, Plesner T, Jakobsen EH, Hansen CT, Jørgensen HB, Delaissé JM.
    J Bone Miner Res; 2013 Aug 17; 28(8):1738-50. PubMed ID: 23427025
    [Abstract] [Full Text] [Related]

  • 10. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
    Broom RJ, Hinder V, Sharples K, Proctor J, Duffey S, Pollard S, Fong PC, Forgeson G, Harris DL, Jameson MB, O'Donnell A, North RT, Deva S, Hanning FJ, Grey A, Findlay MP.
    Clin Genitourin Cancer; 2015 Feb 17; 13(1):50-8. PubMed ID: 25163397
    [Abstract] [Full Text] [Related]

  • 11. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
    Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA, Jung K.
    Eur Urol; 2007 Nov 17; 52(5):1381-7. PubMed ID: 17321667
    [Abstract] [Full Text] [Related]

  • 12. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct 17; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

  • 13. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 17; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 14. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR.
    J Bone Miner Res; 2011 Mar 17; 26(3):530-7. PubMed ID: 20839290
    [Abstract] [Full Text] [Related]

  • 15. Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.
    Bønløkke SE, Rand MS, Haddock B, Arup S, Smith CD, Jensen JEB, Schwarz P, Hovind P, Oturai PS, Jensen LT, Møller S, Eiken P, Rubin KH, Hitz MF, Abrahamsen B, Jørgensen NR.
    Osteoporos Int; 2022 Oct 17; 33(10):2155-2164. PubMed ID: 35729342
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
    Botteman MF, Meijboom M, Foley I, Stephens JM, Chen YM, Kaura S.
    Eur J Health Econ; 2011 Dec 17; 12(6):575-88. PubMed ID: 20809091
    [Abstract] [Full Text] [Related]

  • 17. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid.
    Mountzios G, Terpos E, Syrigos K, Papadimitriou C, Papadopoulos G, Bamias A, Mavrikakis M, Dimopoulos MA.
    Transl Res; 2010 May 17; 155(5):247-55. PubMed ID: 20403580
    [Abstract] [Full Text] [Related]

  • 18. Changes in serum bone turnover markers and bone mineral density Z-score in children with osteogenesis imperfecta after zoledronic acid treatment.
    Jin J, Yue L, Lu Y, Zhen Z, Wu H, Shan X.
    J Investig Med; 2024 Oct 17; 72(7):715-722. PubMed ID: 38715223
    [Abstract] [Full Text] [Related]

  • 19. Bone remodeling markers in the detection of bone metastases in prostate cancer.
    de la Piedra C, Castro-Errecaborde NA, Traba ML, Méndez-Dávila C, García-Moreno C, Rodriguez de Acuña L, Rodriguez-Molina J.
    Clin Chim Acta; 2003 May 17; 331(1-2):45-53. PubMed ID: 12691863
    [Abstract] [Full Text] [Related]

  • 20. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 17; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.